Tocqueville Asset Management L.P. Gilead Sciences, Inc. Transaction History

Tocqueville Asset Management L.P.

$6.27 Billion
Q3 2024

A detailed history of Tocqueville Asset Management L.P. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Tocqueville Asset Management L.P. holds 75,797 shares of GILD stock, worth $6.81 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

75,797

Previous 81,902 7.45%

Holding current value

$6.81 Million

Previous $5.62 Million 13.06%

% of portfolio

0.1%

Previous 0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$66.59 - $83.99 $406,531 - $512,758	-6,105 Reduced 7.45%	75,797 $6.35 Million
Q2 2024 Aug 12, 2024	SELL	$63.15 - $72.88 $628,531 - $725,374	-9,953 Reduced 10.84%	81,902 $5.62 Million
Q1 2024 May 09, 2024	SELL	$71.58 - $87.29 $49,604 - $60,491	-693 Reduced 0.75%	91,855 $6.73 Million
Q4 2023 Feb 12, 2024	SELL	$73.27 - $83.09 $103,090 - $116,907	-1,407 Reduced 1.5%	92,548 $7.5 Million
Q3 2023 Nov 09, 2023	BUY	$73.94 - $80.67 $12,274 - $13,391	166 Added 0.18%	93,955 $7.04 Million
Q2 2023 Aug 11, 2023	SELL	$76.01 - $86.7 $62,860 - $71,700	-827 Reduced 0.87%	93,789 $7.23 Million
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $17,394 - $19,818	225 Added 0.24%	94,616 $7.85 Million
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $3.04 Million - $4.36 Million	-48,715 Reduced 34.04%	94,391 $8.1 Million
Q3 2022 Nov 10, 2022	BUY	$59.54 - $68.01 $1.01 Million - $1.15 Million	16,905 Added 13.4%	143,106 $8.83 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $357,864 - $403,062	-6,200 Reduced 4.68%	126,201 $7.8 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $2.61 Million - $3.27 Million	-45,023 Reduced 25.38%	132,401 $7.87 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $10.3 Million - $11.7 Million	-158,975 Reduced 47.26%	177,424 $12.9 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $3,722 - $4,016	55 Added 0.02%	336,399 $23.5 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $634,382 - $693,153	9,995 Added 3.06%	336,344 $23.2 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $18.9 Million - $21.6 Million	315,154 Added 2815.13%	326,349 $21.1 Million
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $90,640 - $103,280	-1,600 Reduced 12.5%	11,195 $652,000
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $934,418 - $1.17 Million	-15,047 Reduced 54.04%	12,795 $809,000
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $594,273 - $690,060	-8,215 Reduced 22.78%	27,842 $2.14 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $97,828 - $125,303	-1,562 Reduced 4.15%	36,057 $2.7 Million
Q4 2019 Jan 14, 2020	SELL	$61.62 - $67.78 $196,999 - $216,692	-3,197 Reduced 7.83%	37,619 $2.44 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $42,194 - $46,575	-675 Reduced 1.63%	40,816 $2.59 Million
Q2 2019 Jul 31, 2019	SELL	$61.87 - $69.38 $3,093 - $3,469	-50 Reduced 0.12%	41,491 $2.8 Million
Q1 2019 Apr 30, 2019	SELL	$62.53 - $70.05 $1.46 Million - $1.63 Million	-23,282 Reduced 35.92%	41,541 $2.7 Million
Q4 2018 Feb 08, 2019	SELL	$60.54 - $79.0 $865,964 - $1.13 Million	-14,304 Reduced 18.08%	64,823 $4.06 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $47,543 - $52,639	-667 Reduced 0.84%	79,127 $6.11 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $11,354 - $13,244	175 Added 0.22%	79,794 $5.65 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $517,018 - $630,302	-7,098 Reduced 8.19%	79,619 $6 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $2.93 Million - $3.44 Million	-41,212 Reduced 32.21%	86,717 $6.21 Million
Q3 2017 Oct 30, 2017	BUY	$72.11 - $85.47 $9.22 Million - $10.9 Million	127,929	127,929 $10.4 Million

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tocqueville Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Tocqueville Asset Management L.P. with notifications on news.

Account

Tocqueville Asset Management L.P. Gilead Sciences, Inc. Transaction History